中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Cervical Ca PROs in Clinical Practice

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态主动,不招募
赞助商
University Health Network, Toronto

关键词

抽象

Concurrent chemo-radiotherapy followed by intracavitary brachytherapy is standard of care for patients with locally advanced cervical cancer. Although curative, this treatment is challenging and leaves a significant proportion of women with severe toxicity, negatively impacting their quality of life. Although most recover over time, a proportion of women do not. Therefore, evaluation of quality of life becomes increasingly more important as cancer specific outcomes improve. One such method is through patient-reported outcomes (PROs), defined as "any report coming directly from the patient about a health condition and its treatment." This prospective multi-institutional study, involving the Princess Margaret (PM), Odette Regional Cancer Centre(ORCC) and Royal Victoria Regional Health Center (RVH), will assess to feasibility and acceptability of integrating a cervical cancer specific PRO measurement tool into clinical practice. Cervical cancer patients coming for follow-up appointments will be asked to complete the EORTC QLQ-CX24, a validated cervical cancer specific PRO questionnaire. At the end of the study period, Feedback Forms will be completed by participating patients and health care providers to obtain their perspectives regarding the feasibility and acceptability of incorporating the instrument into clinical practice. Future directions include designing an electronic platform and expanding its use in cervical cancer clinics provincially and nationally. The data collected should help identify disease-related symptoms, treatment-related toxicities, facilitate patient-physician communication, shared treatment planning and target intervention strategies.

日期

最后验证: 03/31/2019
首次提交: 02/06/2017
提交的预估入学人数: 02/06/2017
首次发布: 02/08/2017
上次提交的更新: 04/23/2019
最近更新发布: 04/24/2019
实际学习开始日期: 02/26/2017
预计主要完成日期: 10/31/2020
预计完成日期: 10/31/2020

状况或疾病

Cervical Cancer
Radiation Therapy

干预/治疗

Other: Cervical Cancer Patients

Other: Oncologist

-

手臂组

干预/治疗
Cervical Cancer Patients
Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
Other: Cervical Cancer Patients
Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
Oncologist
Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
Other: Oncologist
This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
取样方式Non-Probability Sample
接受健康志愿者
标准

Patient Inclusion Criteria:

1. Adult (> 18 years) English speaking patients

2. Treated with curative intent with chemo-radiotherapy

3. Seen in routine clinic follow-up within 5 years post completion of treatment

Patient Exclusion Criteria:

1. Patients at their anticipated last clinic visit prior to cancer center discharge

2. Patients unable to complete the EORTC QLQ CX-24 questionnaire due to inability to read or write.

3. Non-English speaking patients

4. Patients of the principal investigator. The rationale for this is that patients of the principal investigator who complete the Feedback form may be biased and this may be reflected in the results.

Oncologist Inclusion Criteria:

1. Oncologists who treat cervix cancer

2. Oncologists with at least one consenting patient enrolled in the study

Oncologist Exclusion Criteria:

1) Principal investigator listed on the protocol. The rationale for this is that oncologists who are also investigators on this study may have inherent bias in the study which may be reflected in the results of the Feedback form.

结果

主要结果指标

1. Percentage of EORTC QLQ CX24 questionnaire completed [9 months]

Gather information on feasibility of administering questionnaire

2. Percentage of favorable scores (Agree or strongly agree) on Feedback Form [9 months]

Gather information on acceptability of incorporating the questionnaire in routine follow-up

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge